

Simone P Niclou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4032297/publications.pdf>

Version: 2024-02-01

117
papers

10,429
citations

34105

52
h-index

34986

98
g-index

122
all docs

122
docs citations

122
times ranked

19026
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	27.8	2,132
2	Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3749-3754.	7.1	552
3	Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. <i>Nature Cell Biology</i> , 2015, 17, 1556-1568.	10.3	423
4	Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. <i>Nature Communications</i> , 2019, 10, 1787.	12.8	379
5	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	27.8	320
6	Critical Appraisal of the Side Population Assay in Stem Cell and Cancer Stem Cell Research. <i>Cell Stem Cell</i> , 2011, 8, 136-147.	11.1	287
7	Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17450-17455.	7.1	263
8	In vivo models of primary brain tumors: pitfalls and perspectives. <i>Neuro-Oncology</i> , 2012, 14, 979-993.	1.2	211
9	Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures. <i>EMBO Reports</i> , 2018, 19, .	4.5	186
10	Glioma progression is shaped by genetic evolution and microenvironment interactions. <i>Cell</i> , 2022, 185, 2184-2199.e16.	28.9	163
11	The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. <i>Molecular and Cellular Neurosciences</i> , 2006, 32, 102-117.	2.2	154
12	Slit2 Is a Repellent for Retinal Ganglion Cell Axons. <i>Journal of Neuroscience</i> , 2000, 20, 4962-4974.	3.6	152
13	Formation of Composite Endothelial Cell-Mesenchymal Stem Cell Islets. <i>Diabetes</i> , 2008, 57, 2393-2401.	0.6	139
14	DNA repair mechanisms and their clinical impact in glioblastoma. <i>Mutation Research - Reviews in Mutation Research</i> , 2016, 769, 19-35.	5.5	128
15	EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. <i>Acta Neuropathologica</i> , 2013, 125, 683-698.	7.7	127
16	U251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. <i>Cancer Medicine</i> , 2014, 3, 812-824.	2.8	127
17	Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. <i>Acta Neuropathologica</i> , 2015, 129, 115-131.	7.7	122
18	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	1.2	119

#	ARTICLE	IF	CITATIONS
19	Ciliary Neurotrophic Factor Cell-Based Delivery Prevents Synaptic Impairment and Improves Memory in Mouse Models of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2010, 30, 7516-7527.	3.6	114
20	Lentiviral-mediated transfer of CNTF to schwann cells within reconstructed peripheral nerve grafts enhances adult retinal ganglion cell survival and axonal regeneration. <i>Molecular Therapy</i> , 2005, 11, 906-915.	8.2	112
21	Changes in the expression of protease-activated receptor 1 and protease nexin-1 mRNA during rat nervous system development and after nerve lesion. <i>European Journal of Neuroscience</i> , 1998, 10, 1590-1607.	2.6	111
22	Viral vector-mediated gene expression in olfactory ensheathing glia implants in the lesioned rat spinal cord. <i>Gene Therapy</i> , 2002, 9, 135-146.	4.5	111
23	Altered metabolic landscape in IDH mutant gliomas affects phospholipid, energy, and oxidative stress pathways. <i>EMBO Molecular Medicine</i> , 2017, 9, 1681-1695.	6.9	111
24	Intravitreal Injection of Adeno-associated Viral Vectors Results in the Transduction of Different Types of Retinal Neurons in Neonatal and Adult Rats: A Comparison with Lentiviral Vectors. <i>Molecular and Cellular Neurosciences</i> , 2002, 21, 141-157.	2.2	104
25	The astrocyte/meningeal cell interface is a barrier to neurite outgrowth which can be overcome by manipulation of inhibitory molecules or axonal signalling pathways. <i>Molecular and Cellular Neurosciences</i> , 2003, 24, 913-925.	2.2	102
26	Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. <i>Blood</i> , 2018, 131, 1617-1621.	1.4	101
27	Comprehensive Analysis of Glycolytic Enzymes as Therapeutic Targets in the Treatment of Glioblastoma. <i>PLoS ONE</i> , 2015, 10, e0123544.	2.5	101
28	Drug and cell encapsulation: Alternative delivery options for the treatment of malignant brain tumors. <i>Advanced Drug Delivery Reviews</i> , 2014, 67-68, 142-153.	13.7	100
29	Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4510-4516.	6.4	100
30	Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. <i>Brain Pathology</i> , 2019, 29, 513-529.	4.1	99
31	Glioblastomas are composed of genetically divergent clones with distinct tumorigenic potential and variable stem cell-associated phenotypes. <i>Acta Neuropathologica</i> , 2014, 127, 203-219.	7.7	97
32	Meningeal cell-derived semaphorin 3A inhibits neurite outgrowth. <i>Molecular and Cellular Neurosciences</i> , 2003, 24, 902-912.	2.2	96
33	Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. <i>BMC Neuroscience</i> , 2004, 5, 4.	1.9	91
34	Increased formate overflow is a hallmark of oxidative cancer. <i>Nature Communications</i> , 2018, 9, 1368.	12.8	90
35	RNAi/CRISPR Screens: from a Pool to a Valid Hit. <i>Trends in Biotechnology</i> , 2019, 37, 38-55.	9.3	90
36	Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A. <i>British Journal of Cancer</i> , 2017, 117, 813-825.	6.4	89

#	ARTICLE	IF	CITATIONS
37	Databases for lncRNAs: a comparative evaluation of emerging tools. <i>Rna</i> , 2014, 20, 1655-1665.	3.5	81
38	A Novel Role for Sema3A in Neuroprotection from Injury Mediated by Activated Microglia. <i>Journal of Neuroscience</i> , 2006, 26, 1730-1738.	3.6	79
39	Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. <i>Brain</i> , 2013, 136, 1462-1475.	7.6	79
40	EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. <i>Neuro-Oncology</i> , 2016, 18, 1644-1655.	1.2	78
41	Factors influencing the mechanical stability of alginate beads applicable for immunoisolation of mammalian cells. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2014, 37, 196-208.	3.1	77
42	Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 669-682.	1.2	77
43	Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 455-468.	3.4	75
44	Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. <i>BMC Neuroscience</i> , 2010, 11, 20.	1.9	73
45	Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. <i>Acta Neuropathologica</i> , 2020, 140, 919-949.	7.7	72
46	In vivo animal models for studying brain metastasis: value and limitations. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 695-710.	3.3	70
47	Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. <i>Oncotarget</i> , 2016, 7, 31955-31971.	1.8	69
48	Chemorepellent Axon Guidance Molecules in Spinal Cord Injury. <i>Journal of Neurotrauma</i> , 2006, 23, 409-421.	3.4	68
49	Glioma proteomics: Status and perspectives. <i>Journal of Proteomics</i> , 2010, 73, 1823-1838.	2.4	68
50	iTRAQ-based Proteomics Profiling Reveals Increased Metabolic Activity and Cellular Cross-talk in Angiogenic Compared with Invasive Glioblastoma Phenotype. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2595-2612.	3.8	65
51	Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. <i>Oncolmmunology</i> , 2015, 4, e998107.	4.6	65
52	The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. <i>Cells</i> , 2019, 8, 613.	4.1	60
53	The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. <i>Neuro-Oncology</i> , 2013, 15, 1200-1211.	1.2	58
54	A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. <i>FASEB Journal</i> , 2008, 22, 3120-3128.	0.5	57

#	ARTICLE	IF	CITATIONS
55	Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 604121.	2.8	55
56	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and Î±-KG. <i>Acta Neuropathologica Communications</i> , 2013, 1, 18.	5.2	54
57	Proteomics strategies for target identification and biomarker discovery in cancer. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 3292.	3.0	51
58	A novel multilayer immunoisolating encapsulation system overcoming protrusion of cells. <i>Scientific Reports</i> , 2014, 4, 6856.	3.3	50
59	The angiogenic switch leads to a metabolic shift in human glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now175.	1.2	50
60	Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. <i>Advanced Drug Delivery Reviews</i> , 2014, 76, 98-115.	13.7	48
61	Î±B-Crystallin Is Elevated in Highly Infiltrative Apoptosis-Resistant Glioblastoma Cells. <i>American Journal of Pathology</i> , 2010, 177, 1618-1628.	3.8	47
62	Intercellular transfer of transferrin receptor by a contactâ€, Rab8â€dependent mechanism involving tunneling nanotubes. <i>FASEB Journal</i> , 2015, 29, 4695-4712.	0.5	46
63	Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 689.	4.1	46
64	Cancer stem cells and angiogenesis. <i>Seminars in Cancer Biology</i> , 2009, 19, 279-284.	9.6	44
65	Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM). <i>Molecular and Cellular Proteomics</i> , 2016, 15, 481-492.	3.8	41
66	Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture. <i>Proteome Science</i> , 2014, 12, 39.	1.7	40
67	The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin. <i>Biochemical Journal</i> , 1996, 315, 939-945.	3.7	39
68	A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. <i>PLoS ONE</i> , 2013, 8, e59773.	2.5	39
69	Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 66-74.	7.4	39
70	Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma. <i>Cell Communication and Signaling</i> , 2015, 13, 23.	6.5	39
71	Analysis of the Growth Dynamics of Angiogenesis-Dependent and -Independent Experimental Glioblastomas by Multimodal Small-Animal PET and MRI. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1135-1145.	5.0	38
72	Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity. <i>Scientific Reports</i> , 2020, 10, 2896.	3.3	37

#	ARTICLE	IF	CITATIONS
73	Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. <i>American Journal of Cancer Research</i> , 2016, 6, 2514-2531.	1.4	35
74	The Thrombin Receptor Is Present in Myoblasts and Its Expression Is Repressed upon Fusion. <i>Journal of Biological Chemistry</i> , 1996, 271, 29162-29169.	3.4	34
75	The Thrombin Receptor in the Nervous System. <i>Seminars in Thrombosis and Hemostasis</i> , 1996, 22, 125-133.	2.7	33
76	EGFL7 enhances surface expression of integrin $\alpha_5\beta_1$ to promote angiogenesis in malignant brain tumors. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	33
77	Analysis of the dynamic co-expression network of heart regeneration in the zebrafish. <i>Scientific Reports</i> , 2016, 6, 26822.	3.3	32
78	Cell therapies for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 739-749.	3.1	26
79	A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications. <i>Cancer Research</i> , 2019, 79, 1226-1238.	0.9	26
80	Transcriptional and epigenetic mechanisms underlying astrocyte identity. <i>Progress in Neurobiology</i> , 2019, 174, 36-52.	5.7	26
81	AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. <i>Nature Communications</i> , 2020, 11, 6366.	12.8	24
82	Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?. <i>Neuro-Oncology</i> , 2014, 16, 754-756.	1.2	23
83	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. <i>Cancers</i> , 2019, 11, 2028.	3.7	23
84	PeptideManager: a peptide selection tool for targeted proteomic studies involving mixed samples from different species. <i>Frontiers in Genetics</i> , 2014, 5, 305.	2.3	18
85	Novel facets of glioma invasion. <i>International Review of Cell and Molecular Biology</i> , 2021, 360, 33-64.	3.2	17
86	Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors. <i>STAR Protocols</i> , 2021, 2, 100534.	1.2	16
87	Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1741-1753.	4.3	15
88	Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry. <i>Nature Communications</i> , 2021, 12, 3834.	12.8	15
89	Prothrombin overexpressed in postnatal neurones requires blood factors for activation in the mouse brain. <i>Journal of Neurochemistry</i> , 2004, 88, 1380-1388.	3.9	14
90	Novel ways to target brain tumour metabolism. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 1227-1239.	3.4	13

#	ARTICLE	IF	CITATIONS
91	Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 109-116.	7.4	13
92	Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. <i>Advances in Radiation Oncology</i> , 2019, 4, 268-282.	1.2	13
93	Carboxypeptidase E transmits its anti-migratory function in glioma cells via transcriptional regulation of cell architecture and motility regulating factors. <i>International Journal of Oncology</i> , 2017, 51, 702-714.	3.3	11
94	Cystathionine- β -lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab057.	0.7	10
95	Elucidating tumour-associated microglia/macrophage diversity along glioblastoma progression and under <i>ACOD1</i> deficiency. <i>Molecular Oncology</i> , 2022, 16, 3167-3191.	4.6	9
96	XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase. <i>Nucleic Acids Research</i> , 2021, 49, 9906-9925.	14.5	8
97	Pericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma. <i>Oncotarget</i> , 2018, 9, 24041-24053.	1.8	8
98	Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. <i>Cancers</i> , 2020, 12, 2583.	3.7	6
99	Tumor versus Stromal Cells in Culture—Survival of the Fittest?. <i>PLoS ONE</i> , 2013, 8, e81183.	2.5	5
100	Enzymatic activity of glycosyltransferase GLT8D1 promotes human glioblastoma cell migration. <i>IScience</i> , 2022, 25, 103842.	4.1	5
101	Hub genes in a pan-cancer co-expression network show potential for predicting drug responses. <i>F1000Research</i> , 2018, 7, 1906.	1.6	4
102	Combined Effect of Tissue Stabilization and Protein Extraction Methods on Phosphoprotein Analysis. <i>Biopreservation and Biobanking</i> , 2013, 11, 161-165.	1.0	3
103	Gauging heterogeneity in primary versus recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 907-909.	1.2	3
104	Revival of the VEGF ligand family?. <i>Neuro-Oncology</i> , 2018, 20, 1421-1422.	1.2	3
105	Dual blockade of STAT3 and EGFR: a key to unlock drug resistance in glioblastoma?. <i>Neuro-Oncology</i> , 2020, 22, 440-441.	1.2	3
106	Gene Set Based Integrated Data Analysis Reveals Phenotypic Differences in a Brain Cancer Model. <i>PLoS ONE</i> , 2013, 8, e68288.	2.5	3
107	Hub genes in a pan-cancer co-expression network show potential for predicting drug responses. <i>F1000Research</i> , 2018, 7, 1906.	1.6	3
108	The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz024.	0.7	2

#	ARTICLE	IF	CITATIONS
109	Is there a prominent role for MR spectroscopy in the clinical management of brain tumors?. Neuro-Oncology, 2020, 22, 903-904.	1.2	2
110	Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. Neuro-Oncology Practice, 2020, 7, 249-259.	1.6	1
111	Turning strength into weakness: protein degradation and autophagy as therapeutic targets in glioblastoma?. Neuro-Oncology, 2021, 23, 1041-1043.	1.2	1
112	METB-09IDENTIFYING NOVEL VULNERABILITIES IN OXIDATIVE STRESS PATHWAYS IN IDH1 MUTANT GLIOMA. Neuro-Oncology, 2015, 17, v137.1-v137.	1.2	0
113	ATPS-59IMPROVING EFFICACY OF BEVACIZUMAB TREATMENT IN GLIOBLASTOMA BY TARGETING HIF1 ALPHA. Neuro-Oncology, 2015, 17, v31.2-v31.	1.2	0
114	Highlights of the inaugural ten " the launch of Neuro-Oncology Advances. Neuro-Oncology Advances, 2019, 1, vdz016.	0.7	0
115	Enzymatic Activity of Glycosyltransferase Glt8d1 Promotes Human Glioblastoma Cells Migration. SSRN Electronic Journal, 0, , .	0.4	0
116	Animal Models for Low-Grade Gliomas. , 2013, , 165-175.		0
117	Stem Cell-Associated Heterogeneity in Glioblastoma Is a Result of Intrinsic Tumor Plasticity Shaped by the Microenvironment. SSRN Electronic Journal, 0, , .	0.4	0